Editorial: Advances in the treatment of Hodgkin lymphoma

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 13; p. 1164081
Main Authors Mei, Matthew, Perini, Guilherme, Ramchandren, Radhakrishnan
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 28.02.2023
Subjects
brentuximab vedotin
chemotherapy
elderly
Hodgkin lymphoma
Oncology
stem cell transplantation
chemotherapy
elderly
stem cell transplantation
Hodgkin lymphoma
brentuximab vedotin
Online AccessGet full text

Cover

Author Ramchandren, Radhakrishnan
Mei, Matthew
Perini, Guilherme
AuthorAffiliation 1 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope , Duarte, CA , United States
2 Hospital Israelita Albert Einstein , São Paulo , Brazil
3 Division of Hematology/Oncology, University of Tennessee Health Science Center , Knoxville, TN , United States
AuthorAffiliation_xml – name: 1 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope , Duarte, CA , United States
– name: 3 Division of Hematology/Oncology, University of Tennessee Health Science Center , Knoxville, TN , United States
– name: 2 Hospital Israelita Albert Einstein , São Paulo , Brazil
Author_xml – sequence: 1
  givenname: Matthew
  surname: Mei
  fullname: Mei, Matthew
– sequence: 2
  givenname: Guilherme
  surname: Perini
  fullname: Perini, Guilherme
– sequence: 3
  givenname: Radhakrishnan
  surname: Ramchandren
  fullname: Ramchandren, Radhakrishnan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36925934$$D View this record in MEDLINE/PubMed
BookMark eNpVkU1P5DAMhiPEavlYfgAX1COXGfLhpOleEEIsICFx2ZX2FrmJO1Nom9mkg8S_3w4zIPDFlv3qsez3iO0PcSDGTgWfK2WriyYOfi65VHMhDHAr9tihlApmFai_-5_qA3aS8xOfwmguuPrODpSppK4UHDJ7E9oxpha7n8VVeMHBUy7aoRiXVIyJcOxpGIvYFHcxLJ6nQffar5axxx_sW4NdppNdPmZ_ft38vr6bPTze3l9fPcy8AjvOSihlEFx6qjxAaWXAJnChK8u9Qqg1eVNjLTQQBc1JKqpFJQC10ZpMpY7Z_ZYbIj65VWp7TK8uYuveGjEtHKax9R05jnUDIXALYKCEUItQGl-HYE3w2MiJdbllrdZ1T8FPpyXsvkC_ToZ26RbxxQnOhRJgJsL5jpDivzXl0fVt9tR1OFBcZyetBpBagpqkZ5-XfWx5__0kEFuBTzHnRM2HRHC3sdhtLHYbi93OYvUf9AmZhQ
Cites_doi 10.1200/JCO.21.01056
10.1182/blood.2022015423
10.1056/NEJMoa2206125
10.1001/jamanetworkopen.2022.54669
10.3324/haematol.2022.282266
ContentType Journal Article
Copyright Copyright © 2023 Mei, Perini and Ramchandren 2023 Mei, Perini and Ramchandren
Copyright_xml – notice: Copyright © 2023 Mei, Perini and Ramchandren 2023 Mei, Perini and Ramchandren
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fonc.2023.1164081
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2234-943X
ExternalDocumentID oai_doaj_org_article_0abf4dd08446474db1d76cbdd86dcaf2
PMC10013146
36925934
10_3389_fonc_2023_1164081
Genre Editorial
Commentary
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EJD
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c348t-7472d102ce9c44782dafd015980c3a4b5ec6bab154eed50e23eb1914a5655e693
IEDL.DBID M48
ISSN 2234-943X
IngestDate Wed Aug 27 00:36:42 EDT 2025
Thu Aug 21 18:37:38 EDT 2025
Fri Jul 11 07:59:02 EDT 2025
Mon Jul 21 05:57:51 EDT 2025
Tue Jul 01 02:58:01 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords chemotherapy
elderly
stem cell transplantation
Hodgkin lymphoma
brentuximab vedotin
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c348t-7472d102ce9c44782dafd015980c3a4b5ec6bab154eed50e23eb1914a5655e693
Notes SourceType-Scholarly Journals-1
content type line 23
ObjectType-Editorial-2
ObjectType-Commentary-1
Edited and Reviewed by: Alessandro Isidori, AORMN Hospital, Italy
This article was submitted to Hematologic Malignancies, a section of the journal Frontiers in Oncology
OpenAccessLink https://doaj.org/article/0abf4dd08446474db1d76cbdd86dcaf2
PMID 36925934
PQID 2854425243
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_0abf4dd08446474db1d76cbdd86dcaf2
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10013146
proquest_miscellaneous_2854425243
pubmed_primary_36925934
crossref_primary_10_3389_fonc_2023_1164081
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-02-28
PublicationDateYYYYMMDD 2023-02-28
PublicationDate_xml – month: 02
  year: 2023
  text: 2023-02-28
  day: 28
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in oncology
PublicationTitleAlternate Front Oncol
PublicationYear 2023
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Ansell (B1) 2022; 387
Mei (B3) 2022; 139
Moskowitz (B2) 2021; 39
Ding (B4) 2023
Larsen (B5) 2023; 6
References_xml – volume: 39
  year: 2021
  ident: B2
  article-title: Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.21.01056
– volume: 139
  year: 2022
  ident: B3
  article-title: Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE
  publication-title: Blood
  doi: 10.1182/blood.2022015423
– volume: 387
  year: 2022
  ident: B1
  article-title: Overall survival with brentuximab vedotin in stage III or IV hodgkin’s lymphoma
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa2206125
– volume: 6
  year: 2023
  ident: B5
  article-title: Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985-2010
  publication-title: JAMA Netw Open
  doi: 10.1001/jamanetworkopen.2022.54669
– year: 2023
  ident: B4
  article-title: Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: A multicenter phase II trial
  publication-title: Haematologica
  doi: 10.3324/haematol.2022.282266
SSID ssj0000650103
Score 2.3031209
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 1164081
SubjectTerms brentuximab vedotin
chemotherapy
elderly
Hodgkin lymphoma
Oncology
stem cell transplantation
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA6yB_Eivq0vKngSyrbNNE28qawswnpS8Bbyqi6ureh68N87abrLrghevJWm0PBNmPmGmXxDyFlpBGUqowm3ZZlApfDJMMCcx4IXZGOuHQYzumPDB7h9LB4XRn35nrAgDxyA66fKt5LZlGPeAiVYndmSGW0tZ9aoqvW-GPMWkqnggws_wCCUMTELE_2qqb1iYU7RSTBIebYUiFq9_t9I5s9eyYXgc7NB1jvWGF-G3W6SFVdvkdVRVxffJnxgx17tQ00u4stQ1f-Ix3WM7C6et5LHTRUPG_v0gguTL7Ri86p2yMPN4P56mHQzERJDgU8TZP-5RVJgnDAAGN6tqiyGdMFTQxXowhmmlUZihMGvSF1O0RmLDBQSt8IxQXdJr25qt0_iSpe5thiyNTgwTOhCWMfR3fE808IVETmfASTfgvSFxJTBoyk9mtKjKTs0I3LlIZx_6FWr2xdoS9nZUv5ly4iczgwg8ZT70oWqXfP5If09T_QuOdCI7AWDzH9FmcAcjkJE-JKplvayvFKPn1sl7ayVGwJ28B-7PyRrHpFw3_2I9Kbvn-4YGctUn7SH8xv9duqB
  priority: 102
  providerName: Directory of Open Access Journals
Title Editorial: Advances in the treatment of Hodgkin lymphoma
URI https://www.ncbi.nlm.nih.gov/pubmed/36925934
https://www.proquest.com/docview/2854425243
https://pubmed.ncbi.nlm.nih.gov/PMC10013146
https://doaj.org/article/0abf4dd08446474db1d76cbdd86dcaf2
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3di9NAEB-OE457Eb-NH0cEn4Rokp1sdgWRU-4sQn2y0Ldlv3IWa6JtD7z_3pkkLVbqSwjZkI-ZnZnfsLO_AXhZey2kLUSmQl1n2Fg68xIp5wnIhGwy9s1gpl_kZIaf59X8CLbtrUYBrg-mdtxParZavv796-Y9Gfw7zjgp3r5pupbJCEtB9i8x543Ytygw1Wyn0xHtD4654q4G3G6uFJhpFPNhnfPwU07hREhN6YHAvaDVc_sfAqT_1lX-Fagu78DtEWGm58OUuAtHsb0HJ9NxDf0-qIuwYGYQu3ybng8VAOt00aaEBNNd2XnaNemkC1ffaWB5QxrvftgHMLu8-Ppxko39EzIvUG0yyhTKQADCR-0RCQoE2wQK_1rlXlh0VfTSWUcgigJllcdSkOPWBVoCeVWUWjyE47Zr42NIG1eXLlB4dxjRS-0qHaIi16jKwulYJfBqKyDzc6DJMJResGANC9awYM0o2AQ-sAh3NzLDdX-hW12Z0WBMbrmEMOSK8lWsMbgi1NK7EJQM3jZlAi-2CjBkEbzMYdvYXa8N7wklT1SiSODRoJDdq7YKTUDtqWrvW_ZH2sW3nnW76KmJUD7570Ofwin_5rDh_Rkcb1bX8TlBlo0761N9On6aF2f9pPwDWPPn1A
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Editorial%3A+Advances+in+the+treatment+of+Hodgkin+lymphoma&rft.jtitle=Frontiers+in+oncology&rft.au=Mei%2C+Matthew&rft.au=Perini%2C+Guilherme&rft.au=Ramchandren%2C+Radhakrishnan&rft.date=2023-02-28&rft.issn=2234-943X&rft.eissn=2234-943X&rft.volume=13&rft.spage=1164081&rft_id=info:doi/10.3389%2Ffonc.2023.1164081&rft_id=info%3Apmid%2F36925934&rft.externalDocID=36925934
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon